Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Inflammatory Breast Cancer Stage IV
Interventions: DRUG: Bemcentinib; pembrolizumab
Sponsor: BerGenBio ASA
Collaborators: Merck Sharp & Dohme LLC